BOOSTER THERAPEUTICS
LIVE

Serial Number

97312047

Owner

Booster Therapeutics GmbH

Attorney

Nicholas D. Wells

Filing Date

Mar 14, 2022

Add to watchlist:

No watchlists yet
View on USPTO

BOOSTER THERAPEUTICS Trademark

Serial Number: 97312047

BOOSTER THERAPEUTICS is a trademark filed by Booster Therapeutics GmbH on March 14, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Booster Therapeutics GmbH (3 trademarks)

Schluterstr 36
Berlin D-10629 , DE

Entity Type: 16

Trademark Details

Filing Date

March 14, 2022

Registration Date

August 11, 2026

Goods & Services

Pharmaceutical preparations for the treatment of the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases; Compound drugs and pharmaceuticals for the use in the field of oncology, immunology, inflammatory diseases, and central nervous system disorders to treat the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases, by degrading disease-causing cellular proteins; Compound drugs and pharmaceuticals for the treatment of the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases, by degrading disease-causing cellular proteins; Biological reagents for medical use; Cellular function activating agents for medical purposes; Chemical reagents for medical use; Clinical diagnostic reagents; Diagnostic testing materials for medical use, namely, Diagnostic reagents for medicinal use; Diagnostic substances for medical use; Disinfectants and antiseptics; Drug delivery agents, namely, Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Arsenic, Benzol and Chlorine detoxification agents for medical purposes; Drugs being pharmaceuticals, medical and veterinary preparations for the treatment of for the treatment of the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases, caused by degrading disease-causing cellular proteins; Enzymes for medical purposes; General anaesthetics; Pharmaceuticals, medical and veterinary preparations for the treatment of for the treatment of the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases, caused by degrading disease-causing cellular proteins; Sanitary preparations for medical purposes; Food for babies; Dietary supplements for human beings and animals; Sticking plasters for medical purposes; Materials for medical and surgical dressings; Material for stopping teeth; Dental wax; Disinfectants; Preparations for destroying vermin; Fungicides; Herbicides

Medical laboratory services; Biological research; Clinical research in the field the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases, by degrading disease-causing cellular proteins; Medical research; Scientific research in the nature of conducting clinical trials for others in the field of pharmaceutical products; Research and development for the pharmaceutical industry; Consultancy relating to pharmaceutical research and development; Scientific and technological services, namely, scientific research, analysis and testing research in the field the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases, by degrading disease-causing cellular proteins, and scientific research and Design of computer software relating thereto; Application service provider, namely, Providing online non-downloadable computer software platforms for medical research in the field of drug discovery and drug development; Programming of a drug discovery and development computer software platform for others; Online electronic data storage; Consultancy and assistance services in the nature of website design consultancy and computer software consulting, via an online website and data network platform, in the field of medical sciences including cell metabolism, aging and cell health; Computer services, namely, hosting of an online platform in the nature of online web facilities for the archiving, evaluation, analysation and exchange of data in the fields of biological research, clinical research and medical research

Filing History

ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Jul 24, 2026 ERRR
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Jul 15, 2026 CNTA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 8, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 8, 2026 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 8, 2026 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 8, 2026 GNFN
FINAL REFUSAL E-MAILED
Jan 8, 2026 GNFR
FINAL REFUSAL WRITTEN
Jan 8, 2026 CNFR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 28, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 28, 2025 GNSL
SUSPENSION LETTER WRITTEN
Aug 28, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 17, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 17, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jul 17, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jul 15, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jul 15, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Jul 15, 2025 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 7, 2025 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 6, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 3, 2024 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 2, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
May 2, 2023 GNSL
SUSPENSION LETTER WRITTEN
May 2, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 4, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 3, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 3, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 3, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jan 3, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jan 3, 2023 CNRT
ASSIGNED TO EXAMINER
Dec 23, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 18, 2022 NWOS
NEW APPLICATION ENTERED
Mar 17, 2022 NWAP